Study finds injectable treatment for blood clots in advanced cancer patients increases
The use of an injectable, clot-preventing drug known as Low Molecular Weight Heparin to treat patients with advanced cancer complicated by blood clots increased steadily between 2000 and 2007, according to a new study published in The Oncologist, funded by the National Cancer Institute and led by Kaiser Permanente Colorado. However, despite previous research indicating LMWH is the preferred first-line treatment for cancer patients experiencing blood clots, use of LMWH is low compared to another commonly used anticoagulant, warfarin.
The study was conducted by a team of Kaiser Permanente researchers from Colorado, Oregon, Washington and Northern California, Dana-Farber Cancer Institute and Group Health Research Institute.
Venous thromboembolism, or blood clots, are common and serious complications in cancer patients. Anticoagulation drugs work to prevent additional clots from forming, while the body partially or completely dissolves the initial clot.
The study examined data from electronic health records of four health plans participating in the Cancer Research Network, a consortium of integrated health plans that pool data for research. Patients were identified with advanced breast cancer, colorectal, lung and prostate cancer who received treatment between January 2000 and December 2008 at Group Health Cooperative and Kaiser Permanente regions in Colorado, Northern California and Oregon and Washington.
Over the entire study period, 25 percent of patients received LMWH as a primary treatment for blood clots. A majority of patients, 74 percent overall, received warfarin-based therapy.
"Blood clots are a frequent complication in patients with cancer, so it's essential to understand patterns of care and adherence to guideline recommendations for them," said Dr. Tom Delate, PhD, study lead author. "Current medical literature on this topic is limited, so our findings will add tremendously to this knowledge gap and, hopefully, stimulate discussions on the need for comparative effectiveness research evaluations between blood clot anticoagulation therapies."
A randomized controlled trial in July 2003 demonstrated that LMWH was more effective at preventing recurrent clots than warfarin in patients with cancer. In addition, current clinical guidelines from the American College of Chest Physicians, American Society of Clinical Oncology and National Comprehensive Cancer Network recommend LMWH treatment for cancer-related blood clots.
The study did not determine why warfarin continued to be the preferred anti-coagulation therapy for advanced cancer patients. Warfarin does have a long history of use in treatment of blood clots, and high-quality anticoagulation monitoring services are available in the health plans studied, possibly resulting in a high level of physician comfort with warfarin. In addition, because LMWH requires daily injections, patients may prefer taking warfarin since it is available in tablet form.
According to Dr. Delate, Clinical Pharmacy Research Scientist at Kaiser Permanente Colorado, next steps should be to study why use of LMWH is low compared to warfarin and to compare the effectiveness of LMWH compared with warfarin in patients with advanced cancer.
Provided by
Kaiser Permanente
-
Preventive use of blood thinners by cancer patients could save lives, cut costs
Dec 13, 2011 |
not rated yet |
0
-
New anti-clotting drug added to recommendations for treating irregular heartbeat
Feb 14, 2011 |
not rated yet |
0
-
Genetics determine optimal drug dose of common anticoagulant
Aug 21, 2007 |
not rated yet |
0
-
New scorecard identifies patients at highest risk on blood thinners
Aug 04, 2011 |
not rated yet |
0
-
Cancer patients with blood clots gain no benefit from adding IVCF to fondaparinux
Jul 07, 2011 |
not rated yet |
0
-
Motion perception revisited: High Phi effect challenges established motion perception assumptions
Apr 23, 2013 |
3 / 5 (2) |
2
-
Anything you can do I can do better: Neuromolecular foundations of the superiority illusion (Update)
Apr 02, 2013 |
4.5 / 5 (11) |
5
-
The visual system as economist: Neural resource allocation in visual adaptation
Mar 30, 2013 |
5 / 5 (2) |
9
-
Separate lives: Neuronal and organismal lifespans decoupled
Mar 27, 2013 |
4.9 / 5 (8) |
0
-
Sizing things up: The evolutionary neurobiology of scale invariance
Feb 28, 2013 |
4.8 / 5 (10) |
14
-
How can there be a term called "intestinal metaplasia" of stomach
8 hours ago
-
Pressure-volume curve: Elastic Recoil Pressure don't make sense
May 18, 2013
-
If you became brain-dead, would you want them to pull the plug?
May 17, 2013
-
MRI bill question
May 15, 2013
-
Ratio of Hydrogen of Oxygen in Dessicated Animal Protein
May 13, 2013
-
Alcohol and acetaminophen
May 13, 2013
- More from Physics Forums - Medical Sciences
More news stories
Poliovirus vaccine trial shows early promise for recurrent glioblastoma
An attack on glioblastoma brain tumor cells that uses a modified poliovirus is showing encouraging results in an early study to establish the proper dose level, researchers at Duke Cancer Institute report.
Cancer
1 hour ago |
not rated yet |
0
Racial disparities in the surgical management of non-small cell lung cancer
The surgical management of non-small cell lung cancer (NSCLC) in U.S. hospitals varies widely depending on the race of the patient, according to a new study.
Cancer
5 hours ago |
not rated yet |
0
Treatment with A1-PI slows the progression of emphysema in Alpha-1 antitrypsin deficiency
Treatment with an Alpha-1 proteinase inhibitor (A1-PI), a naturally occurring protein that protects lung tissue from breakdown and protects the lung's elasticity, is effective in slowing the progression of emphysema in patients ...
Cancer
5 hours ago |
not rated yet |
0
New tumour-killer shows great promise in suppressing cancers
Scientists from Nanyang Technological University (NTU) and Lund University, Sweden, have bioengineered a novel molecule which has been proven to successfully kill tumour cells.
Cancer
5 hours ago |
5 / 5 (1) |
0
New factor to control oncogene-induced senescence
An article published on the journal Nature describes the major role that Pyruvate dehydrogenase (PDH) —an enzyme of cellular energy metabolism— plays in the regulation of the cellular senescence induce ...
Cancer
6 hours ago |
not rated yet |
0
Drugs found to both prevent and treat Alzheimer's disease in mice
Researchers at USC have found that a class of pharmaceuticals can both prevent and treat Alzheimer's Disease in mice.
Decisions to forgo life support may depend heavily on the ICU where patients are treated
The decision to limit life support in patients in the intensive care unit (ICU) appears to be significantly influenced by physician practices and/or the culture of the hospital, suggests new findings from researchers at the ...
Better behavior after tonsil/adenoid surgery for kids with sleep breathing trouble?
Children with obstructive sleep apnea who had a common surgery to remove their tonsils and adenoids showed notable improvements in behavior, quality of life and other symptoms compared to those treated with "watchful waiting" ...
If you can remember it, you can remember it wrong
(Medical Xpress)—Native peoples in regions where cameras are uncommon sometimes react with caution when their picture is taken. The fear that something must have been stolen from them to create the photo ...
B vitamins could delay dementia
(Medical Xpress)—Despite spending billions of dollars on research and development, drug companies have been unable to come up with effective treatments for dementia and Alzheimer's Disease (AD). Now, A. ...
Insight into the dazzling impact of insulin in cells
Australian scientists have charted the path of insulin action in cells in precise detail like never before. This provides a comprehensive blueprint for understanding what goes wrong in diabetes.